Company profile: Alpheus Medical
1.1 - Company Overview
Company description
- Provider of a non-invasive sonodynamic therapy platform for solid body cancers that uses ultrasound to activate a cancer-targeting drug, including an SDT platform for outpatient treatment of recurrent high-grade gliomas and CV-01, an investigational drug-device using low-intensity, large-field ultrasound to target cancer cells across the brain hemisphere; CV-01 is in Phase 1 clinical trials for recurrent glioblastoma.
Products and services
- CV-01 Delivery of Sonodynamic Therapy (SDT): Investigational non-invasive drug-device combination delivering low-intensity, large-field ultrasound to activate an anti-cancer drug throughout the entire brain hemisphere
- In Phase 1 trials for recurrent glioblastoma
- Sonodynamic Therapy (SDT) Platform: Non-invasive system using ultrasound to activate a cancer-targeting drug, architected for outpatient treatment of recurrent high-grade gliomas, including glioblastomas
- Addresses solid body cancers.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Alpheus Medical
Nanovi
HQ: Denmark
Website
- Description: Provider of biomaterials-based medical devices for improving guidance and precision in cancer radiotherapy. Offers BioXmark, a liquid fiducial marker that enhances target visibility on imaging for high-precision radiation therapy, including proton beam therapy; and PetXmark, a liquid fiducial marker for dogs and cats to radiographically mark subcutaneous tissue and guide radiotherapy of skin and subcutaneous tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nanovi company profile →
Artbio
HQ: United States
Website
- Description: Provider of clinical-stage alpha radioligand medicines and enabling technologies, including AB001, a 212Pb-based radiopharmaceutical candidate for prostate cancer in Phase I/II trials; AlphaDirect technology for isolating Pb-212 to enable distributed manufacturing; and a distributed end-to-end manufacturing network to deliver therapeutic candidates rapidly and flexibly.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Artbio company profile →
ProCure
HQ: United States
Website
- Description: Provider of a network of proton therapy centers in the United States, offering proton therapy including pencil beam scanning; physician case evaluations; initial consultation and planning; treatment sessions typically 5 days a week for 4–7 weeks; and regular radiation oncologist check-ins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ProCure company profile →
ArcherDX
HQ: United States
Website
- Description: Provider of NGS-based assay solutions advancing molecular pathology, using proprietary Anchored Multiplex PCR (AMP) chemistry and Archer Analysis software to detect genetic mutations for solid tumor, blood cancer, and genetic disease research. Offers VARIANTPlex DNA panels, FUSIONPlex RNA panels, LIQUIDPlex ctDNA panels, IMMUNOVerse immune profiling assays, and an Assay Marketplace for custom NGS panels.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ArcherDX company profile →
Anaveon
HQ: Switzerland
Website
- Description: Provider of IL-2-based immunotherapies developing selective IL-2 complexes that promote effector T cell functions as immune adjuvants for cancer, with candidates including ANV419, an IL-2 agonist that favors effector over regulatory T cells and shows clinical efficacy, and ANV600, a bispecific targeting IL-2 to tumor-specific cells, with Phase 1/2 planned for Q2/2024.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Anaveon company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Alpheus Medical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Alpheus Medical
2.2 - Growth funds investing in similar companies to Alpheus Medical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Alpheus Medical
4.2 - Public trading comparable groups for Alpheus Medical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →